Valion Bio, Inc. 8-K

What Happened

• Valion Bio, Inc. announced that its stockholders approved an amendment to the Amended and Restated 2021 Equity Incentive Plan to increase the number of shares authorized for issuance by 2,581,608 shares. The Board had approved the amendment on January 29, 2026, and the Plan Amendment became effective on May 28, 2026 following stockholder approval. Additional details were included in the Company’s definitive proxy statement filed April 30, 2026. The Second Amendment to the 2021 Plan is attached as Exhibit 10.1 to the 8-K.

Key Details

• Approved increase: 2,581,608 shares of common stock added to the 2021 Equity Incentive Plan.
• Board approval: January 29, 2026 (subject to stockholder approval).
• Stockholder approval / Effective date: May 28, 2026.
• Proxy statement filed: April 30, 2026; Second Amendment attached as Exhibit 10.1 to the 8-K.

Why It Matters

• The amendment gives Valion Bio the ability to grant more equity awards (stock options, restricted stock, etc.) to employees, directors and consultants under its incentive plan, which the company can use for hiring, retention and compensation.
• For investors, the key implications are potential future dilution if the new shares are issued as awards; the filing documents the exact share increase and the effective date but does not disclose immediate issuances or financial impacts.
• No other material officer or director departures or financial results were disclosed in this 8-K; the filing focuses on the equity plan amendment.